Dr. Daniel Y. Wu, M.D., PH.D.
Hematology & Oncology (Hematology & Oncology Physician)
1660 S Columbian Way, 111-onc
Seattle, WA 98108
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in Washington since 1993, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WA license MD00031148 (first issued 1993; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $151,168 in research payments for these studies, mostly to the institutions running them.
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Daiichi Sankyo Inc. · Active, not recruiting · NCT05555732 - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo Inc. · Active, not recruiting · NCT05215340 - A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company · Recruiting · NCT06119581
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.